- Home
- PZC vs SGMO Comparison
PZC vs SGMO Comparison
Compare PZC & SGMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PZC
- SGMO
- Stock Information
- Founded
- PZC 2002
- SGMO 1995
- Country
- PZC United States
- SGMO United States
- Employees
- PZC N/A
- SGMO N/A
- Industry
- PZC Investment Managers
- SGMO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PZC Finance
- SGMO Health Care
- Exchange
- PZC Nasdaq
- SGMO Nasdaq
- Market Cap
- PZC 140.1M
- SGMO 122.8M
- IPO Year
- PZC N/A
- SGMO 2000
- Fundamental
- Price
- PZC $6.04
- SGMO $0.59
- Analyst Decision
- PZC
- SGMO Buy
- Analyst Count
- PZC 0
- SGMO 6
- Target Price
- PZC N/A
- SGMO $4.50
- AVG Volume (30 Days)
- PZC 48.2K
- SGMO 5.2M
- Earning Date
- PZC 01-01-0001
- SGMO 08-05-2025
- Dividend Yield
- PZC 4.68%
- SGMO N/A
- EPS Growth
- PZC N/A
- SGMO N/A
- EPS
- PZC N/A
- SGMO N/A
- Revenue
- PZC N/A
- SGMO $63,756,000.00
- Revenue This Year
- PZC N/A
- SGMO $1.29
- Revenue Next Year
- PZC N/A
- SGMO $1.60
- P/E Ratio
- PZC N/A
- SGMO N/A
- Revenue Growth
- PZC N/A
- SGMO 239.92
- 52 Week Low
- PZC $6.30
- SGMO $0.41
- 52 Week High
- PZC $8.20
- SGMO $3.18
- Technical
- Relative Strength Index (RSI)
- PZC 26.04
- SGMO 60.91
- Support Level
- PZC $6.13
- SGMO $0.50
- Resistance Level
- PZC $6.12
- SGMO $0.65
- Average True Range (ATR)
- PZC 0.04
- SGMO 0.04
- MACD
- PZC -0.01
- SGMO 0.01
- Stochastic Oscillator
- PZC 0.00
- SGMO 64.22
About PZC PIMCO California Municipal Income Fund III of Beneficial Interest
PIMCO CA Muni Income Fund III operates as a closed-end management investment company. The investment objective of the fund is to seek to provide current income exempt from federal and California income tax. Its portfolio of investments includes investment in different sectors such as education, healthcare, industrial and others.
About SGMO Sangamo Therapeutics Inc.
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.